Polymyositis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Polymyositis is characterized by chronic muscle inflammation and weakness involving the skeletal muscles and the weakness generally starts in the proximal muscles such as muscles of the upper arm and shoulder and the upper leg and hip. Polymyositis has non-specific clinical features including proximal muscle weakness and elevated serum creatine kinase. The age of onset is over 20 years, with most patients aged 45-60 years. The disease develops gradually over a period of 3 to 6 months with a variable impact on physical capacities: difficulty lifting objects, raising arms, kneeling, and climbing or descending stairs.

 

·       Arthralgia may be found and myalgia is reported in less than 30% of patients. Other signs include neck flexor weakness, fatigue, stiffness, weight loss anorexia, dysphagia, and less commonly dysphonia.

·       The estimated annual incidence cases range between 1.5 to 2.2 cases per 150,000 to 250,000 individuals and the prevalence ranges between 1 to 2 cases per 50,000 individuals.

 

The competitive landscape of Polymyositis includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Polymyositis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Polymyositis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Polymyositis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          KZR-616           Kezar Life Sciences, Inc.           Phase 2

2          Ustekinumab     Janssen Pharmaceutical K.K.     Phase 3

3          Adrenocorticotropic Hormone Gel           Mallinckrodt      Phase 2

4          tocilizumab        Genentech, Inc. Phase 2

5          PN-101 Paean Biotechnology Inc.          Phase 2

6          Tacrolimus        Astellas Pharma Inc      Phase 2 Phase 3

7          Abatacept subcutaneous           Bristol-Myers Squibb      Phase 3

8          Ravulizumab     Alexion Pharmaceuticals            Phase 3

9          PF1801 Immunoforge Inc.          Phase 2

10        Lenabasum       Corbus Pharmaceuticals Inc.     Phase 3

Continued.